CM
BIO icon

Corvex Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Corvex Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,000
Closed -$226K – 31
2017
Q2 		$226K Sell
1,000
-846,141
-100% -$184M 0.01% 35
2017
Q1 		$169M Buy
847,141
+359,887
+74% +$69.3M 4.68% 6
2016
Q4 		$88.8M Hold
487,254
– – 1.52% 19
2016
Q3 		$79.8M Hold
487,254
– – 1.5% 13
2016
Q2 		$69.7M Buy
+487,254
New +$69.5M 0.93% 21

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Corvex Management's BIO Position: Q3 2017 in Review

Corvex Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2017, closing a stake of 1,000 shares — an estimated $226K sold.

Corvex Management first reported a position in BIO in Q2 2016 and held it in 5 quarters. The position peaked at $169M in Q1 2017. 271 funds tracked by Wall St. Rank hold BIO as of Q3 2017.

  • Corvex Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2017 after selling out during the quarter.
  • Corvex Management sold 1,000 Bio-Rad Laboratories Class A shares in Q3 2017, an estimated $226K.
  • Corvex Management first reported a position in Bio-Rad Laboratories Class A in Q2 2016 and held it in 5 quarters.
  • Corvex Management's Bio-Rad Laboratories Class A position peaked at $169M in Q1 2017.
  • 271 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2017.

Based on Corvex Management's 13F filing for Q3 2017, filed 14 Nov 2017.